Research in home high flow therapy for COPD

Discover key findings from recent clinical research on the mechanisms of action of home high-flow therapy and the clinical outcomes in patients with COPD.

The HiFAE trial

HiFAE (home high-flow therapy with oxygen to reduce acute exacerbations of COPD) is a randomised, controlled trial to evaluate the efficacy of home high-flow therapy with oxygen versus standard oxygen therapy in patients with COPD. This ongoing study is being conducted at 18 centres in France (N=406). The primary endpoint is the time to first hospital admission for AECOPD or death.

The EPiC Trial

EPiC (Exacerbation Prevention in COPD using home High Flow therapy) is a UK multi-centre, randomised, controlled trial to investigate the effect of home High-Flow Therapy (HFT) as an adjunct to usual medical care on admission-free survival following severe exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

EPiC Trial Logo ResMed

What are the clinical benefits of home high flow therapy?

In this page, “HFT” refers exclusively to nasal HFT.

The clinical benefits of home high flow therapy (HFT) include:

Improved secretion management1

Patient comfort (by providing heated and humidified inhaled gas to the patient)

Reduced dyspnoea during high intensity exercise2-4

Improved breathing/respiration and reduced work of breathing (WOB). 5

In COPD patients with hypoxemic respiratory failure, high flow therapy (HFT) significantly:6,7

Reduced acute exacerbations of COPD (AECOPD),

Reduced rates of hospital admission and symptoms – increasing the time to first exacerbation

Improved patient quality of life (QoL).

HFT is simple and easy-to-operate and delivers both clinical and patient outcome benefits in domiciliary use for COPD. HFT is currently used in the acute hospital setting in adults and is emerging as an option for long-term home use in COPD patients. 6,7

Mechanisms of action and clinical benefits

HFT works via multiple mechanisms including mucociliary clearance and secretion management, and improved respiratory mechanics which reduce WOB and improves patient comfort.1,5,11,12,13

HFT key mechanisms of action illustration

Outcomes and patient benefits

Adjunctive home HFT can reduce acute exacerbation and hospitalisation rates in COPD patients,6,7 and improve symptoms such as mucus retention1, cough1 and dyspnoea during high intensity exercise, 2-4 whilst maintaining or improving patient QoL vs usual care. 6,7

predicted hospitalisation rate per patient per year by HFT usage illustration

Patient comfort and quality of life

Patients with COPD receiving long-term HFT at home have shown preserved or improved QoL scores vs those receiving usual care, including LTOT alone.6,7 HFT also seems to be well tolerated by patients7 and supports patient comfort by improving mucociliary clearance and secretion management1 and reducing dyspnoea during high intensity exercise. 2-4


Lumis™ HFT

ResMed high-flow therapy device supports comfortable therapy for COPD patients at home and is designed for ease of setup and use.

Non contractual picture of the nasal cannula – Use only nasal cannulas recommended by ResMed


  1. Hasani A, et al. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis 2008;5:81-86.
  2. Cirio S, Piran M, Vitacca M, Piaggi G, Ceriana P, Prazzoli M, et al. Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation. Respiratory Medicine 2016;118:128–32.
  3. Neunhäuserer D, Steidle-Kloc E, Weiss G, Kaiser B, Niederseer D, Hartl S, et al. Supplemental Oxygen During High-Intensity Exercise Training in Nonhypoxemic Chronic Obstructive Pulmonary Disease. The American Journal of Medicine 2016;129(11):1185–93.
  1. Chatila W, Nugent T, Vance G, Gaughan J, Criner GJ. The Effects of High-Flow vs Low-Flow Oxygen on Exercise in Advanced Obstructive Airways Disease. Chest 2004;126(4):1108–15.
  2. Fraser JF, et al. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016;71:759-761.
  3. Storgaard LH, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 2018;13:1195-1205.
  4. Rea H, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med 2010;104:525-533.
  5. Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, et al. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD Patients: A Multicenter, Randomized Crossover Trial. Annals of the American Thoracic Society. 2017.
  6. Elshof J, Duiverman ML. Clinical Evidence of Nasal High-Flow Therapy in Chronic Obstructive Pulmonary Disease Patients. Respiration 2020;99:140-153.
  7. Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respir Care 2016;61:529-541.
  8. Vogelsinger H, et al. Efficacy and safety of nasal high-flow oxygen in COPD patients. BMC Pulm Med 2017;17:143.
  9. Biselli P, Fricke K, Grote L, Braun AT, Kirkness J, Smith P, et al. Reductions in dead space ventilation with Nasal High Flow depend on physiologic dead space volume – Metabolic hood measurements during sleep in patients with COPD and controls. European Respiratory Journal. 2018.
  10. McKinstry S, Pilcher J, Bardsley G, Berry J, Van de Hei S, Braithwaite I, et al. Nasal high flow therapy and PtCO2 in stable COPD: A randomized controlled cross-over trial. Respirology. 2017.